晚期癌症患者系统评价的方法学质量极低:一项方法学研究
该研究评估了晚期癌症患者干预性系统评价(SR)的方法学质量及异质性考虑情况,检索2010年1月至2019年7月三个数据库,纳入261篇SR。采用AMSTAR 2评估,发现88.1%的SR质量为极低,主要因未注册及未报告排除全文的理由;异质性未探索者占19.5%。
要点
- 晚期癌症患者的干预性SR中,88.1%方法学质量极低。
- 质量极低主要因未注册(85.1%)和未报告排除全文理由(83.5%)。
- 19.5%的SR完全未探索试验结果的异质性。
核心结论
- 晚期癌症患者干预性系统评价的方法学质量普遍极低,且对异质性的考虑不足。
研究设计与样本
- 方法学研究(注册号CRD42019134904),检索2010年1月至2019年7月三个数据库。
- 纳入至少包含4项随机对照试验且荟萃分析结果有统计学意义的干预性系统评价,共261篇。
- 使用AMSTAR 2评估方法学质量,并将异质性考虑分为临床异质性、方法学异质性、两者兼顾及未探索。
主要发现
- 从6234条文献中纳入261篇系统评价。
- 230篇(88.1%)系统评价质量为极低。
- 209篇(80.1%)因未注册(222篇,85.1%)合并未报告排除全文及排除理由缺失(218篇,83.5%)被归为极低质量。
- 51篇(19.5%)完全未探索试验结果的异质性;117篇(44.8%)考虑了临床异质性,13篇(5.0%)考虑了方法学异质性,80篇(30.7%)两者均考虑。
临床怎么用
- 在系统评价培训中纳入这些发现,可提高作者和同行评审对质量标准的认识,并改善未来系统评价的质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the methodological quality and the consideration of heterogeneity in systematic reviews (SRs). STUDY DESIGN AND SETTING: We conducted a methodological study (CRD42019134904) and searched three databases from January 2010 to July 2019. Interventional SRs with a statistically significant meta-analysis of at least four randomized controlled trials in advanced cancer patients were included. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) 2 was used to evaluate the SRs' methodological quality. The consideration of heterogeneity was categorized in clinical or/and methodological heterogeneity and not explored. RESULTS: From 6234 identified references, 261 SRs were included. Most SRs had a critically low quality (230, 88.1%). The majority of them (209, 80.1%) was classified as critically low because of non-registration (222, 85.1%) combined with the non-reporting of excluded full-texts and missing justifications for exclusion (218, 83.5%). Heterogeneity in trial results was not explored at all in 51 (19.5%) SRs whereas clinical heterogeneity was considered in 117 (44.8%), methodological heterogeneity in 13 (5.0%), and both clinical and methodological heterogeneity in 80 (30.7%) SRs. CONCLUSION: The consideration of these findings in trainings for review authors and peer reviewers could improve the awareness of quality criteria and the quality of future SRs. TRIAL REGISTRATION: PROSPERO-ID: CRD42019134904.
引用
- Siemens W, Schwarzer G, Rohe MS, et al. Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients-A methodological study. J Clin Epidemiol. 2021. PMID: 33741503. doi:10.1016/j.jclinepi.2021.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。